AKT1 and dry eye syndrome: To interrogate pathway involvement, cells were additionally treated with the AKT activator SC79 (10 μM) or the AKT inhibitor MK-2206 (2.5 μM).<h4>Results</h4>A total of 203 overlapping targets were identified between WGS-related and dry eye-related target sets.